Your browser doesn't support javascript.
loading
The bioenergetic landscape of cancer.
Zunica, Elizabeth R M; Axelrod, Christopher L; Gilmore, L Anne; Gnaiger, Erich; Kirwan, John P.
Afiliación
  • Zunica ERM; Integrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, 70808, USA.
  • Axelrod CL; Integrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, 70808, USA.
  • Gilmore LA; Department of Clinical Nutrition, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
  • Gnaiger E; Oroboros Instruments, Innsbruck, Austria.
  • Kirwan JP; Integrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, 70808, USA. Electronic address: john.kirwan@pbrc.edu.
Mol Metab ; 86: 101966, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38876266
ABSTRACT

BACKGROUND:

Bioenergetic remodeling of core energy metabolism is essential to the initiation, survival, and progression of cancer cells through exergonic supply of adenosine triphosphate (ATP) and metabolic intermediates, as well as control of redox homeostasis. Mitochondria are evolutionarily conserved organelles that mediate cell survival by conferring energetic plasticity and adaptive potential. Mitochondrial ATP synthesis is coupled to the oxidation of a variety of substrates generated through diverse metabolic pathways. As such, inhibition of the mitochondrial bioenergetic system by restricting metabolite availability, direct inhibition of the respiratory Complexes, altering organelle structure, or coupling efficiency may restrict carcinogenic potential and cancer progression. SCOPE OF REVIEW Here, we review the role of bioenergetics as the principal conductor of energetic functions and carcinogenesis while highlighting the therapeutic potential of targeting mitochondrial functions. MAJOR

CONCLUSIONS:

Mitochondrial bioenergetics significantly contribute to cancer initiation and survival. As a result, therapies designed to limit oxidative efficiency may reduce tumor burden and enhance the efficacy of currently available antineoplastic agents.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Metabolismo Energético / Mitocondrias / Neoplasias Límite: Animals / Humans Idioma: En Revista: Mol Metab Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Metabolismo Energético / Mitocondrias / Neoplasias Límite: Animals / Humans Idioma: En Revista: Mol Metab Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos